Detall de la convocatòria


Objectiu de la convocatòria
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.
Característiques principals
Topics of the 17th Call:
  • Topic 1: Optimising future obesity treatment
  • Topic 2: Open access chemogenomics library and chemical probes for the druggable genome
  • Topic 3: Intelligent prediction and identification of environmental risks posed by human medicinal products
  • Característiques principals
    This Call is being run in a two-stage submission and evaluation process.
  • Stage 1 submission deadline: 25 April 2019 (17:00:00 Brussels time)
  • Stage 2 submission deadline: 07 November 2019 (17:00:00 Brussels time)
  • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    • Carol Barnwell, [email protected]. Ext.: 1670
    • Marta López, [email protected] Ext.: 1576
    Convocatòria (URL)
    IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources.